To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Ciprofloxacin (Cipro InhaIe, BAYQ3939)

Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days

DRUG

Placebo

Placebo TID for 10 days

Trial Locations (1)

Yufu